Introduction
Injectable hydrogels have been applied as delivery vehicles for various drugs in the field of regenerative medicine. [1] These hydrogels are applicable via minimal invasive procedures, integrate perfectly with surrounding tissue at the injection site, and are able to enclose and deliver drugs or other bioactive compounds. [2, 3] To enable the further development and optimization of hydrogels for applications in the clinic where specific organs or organ regions are targeted, it would be useful to be able to noninvasively monitor the hydrogel in vivo.
www.advancedsciencenews.com www.advhealthmat. de and contrast. [23] MRI is also increasingly applied for guided interventional procedures, including minimal invasive therapies. [24] Conveniently, this implies that contrast enhanced MRI can be employed for both the guided injection with simultaneous visualization of the hydrogel and for postinjection imaging of the injection site giving direct feedback on the success of the procedure. [25] Several examples of either physically mixed hydrogels and contrast agents or hydrogels chemically functionalized with a contrast agent have been reported, which could be distinguished from adjacent tissue in vivo. [9, [26] [27] [28] [29] Physically mixing the agent with the hydrogelator beforehand is the most straightforward approach, but leakage of the agent from the hydrogel can then compromise the ability for accurate visualization of the hydrogel. A preferable method is therefore to use chemical labeling. Indeed, an excellent comparison carried out in a chitosan hydrogel system by Liu et al. demonstrated the superiority of chemical label incorporation over physical mixing. [30] By using supramolecular interactions between the MRI contrast agent and the hydrogelator biomaterial, one can ideally combine the ease of simply mixing both components in any desirable ratio (a favorable feature of physical mixing) with guaranteed co-localization of hydrogel and label (a favorable feature of the chemical incorporation approach). However, supramolecular contrast agent labeling is still considered particularly challenging, as too fast leakage of the MRI label or too fast erosion of the hydrogel can still occur. To the best of our knowledge, only successful examples of supramolecular contrast agent incorporation based on peptide nanofibers have been reported. [31] [32] [33] A shear thinning and shear recovery Gd(III)-labeled peptide hydrogel was injected in the abdominal cavity of a mouse, which was successfully monitored with MRI. [32] Recently, it was shown that guest molecules can be modularly functionalized with a UPy moiety to interact in dilute solution with the aforementioned UPy-PEG hydrogelator. [34] Here, we apply this modular supramolecular principle in the concentrated hydrogel regime, by design of a UPy-functionalized Gd(III)-DOTA complex (UPy-Gd) for enhanced MR imaging of the injected UPy-PEG hydrogel (Figure 1) . First the design, synthesis, and in vitro relaxivity measurements of UPy-Gd are described. Retention of UPy-Gd in the UPy-PEG hydrogel was then studied with MRI, to verify its supramolecular incorporation. Furthermore, MRI imaging studies were performed to study the location of the hydrogel injected in an explanted pig heart. For comparison, experiments were performed in parallel with UPy-PEG hydrogels physically mixed with the commercially available contrast agent Gadoteridol. Finally, an in vivo experiment was performed to study the location of the hydrogel in the pig heart after a catheter and MRI guided intramyocardial injection.
Results and Discussion

Synthesis and Molecules
A Gd(III)-DOTA complex was conjugated to a UPy moiety via a short and discrete oligo ethylene glycol (OEG) spacer. The synthesis commenced by the reaction of the N-hydroxysuccinimide (NHS) ester and primary amine of the two precursors to form UPy-DOTA. After coupling, UPy-DOTA was complexed with Gd(OAc) 3 in water to produce the UPy functionalized Gd(III)-DOTA derived contrast agent UPy-Gd I in an overall yield of 60%. In our studies, contrast agent UPy-Gd is proposed to have an affinity via specific noncovalent interactions for the supramolecular hydrogelator UPy-PEG II, as both contain the same UPy-C 6 -urea-C 12 -anchoring unit. As a reference, the nonUPy-functionalized commercially available MRI contrast agent Gadoteridol III was used as an MRI label that can be mixed in physically (Figure 2) .
Crucial for the paramagnetic Gd(III) based contrast agents is the stable chelation of Gd(III) into the ligand (in this case DOTA). Free Gd(III) is a toxic heavy metal similar in size to Ca(II), and this resemblance leads to competitive inhibition of biological processes and therefore severe toxicity. [35] After synthesis of UPy-Gd, the absence of free Gd(III) in the product was initially confirmed with the xylenol orange test. Furthermore, a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed with human vena saphena cells to determine possible cytotoxicity of UPy-Gd compared to the commercial Gadoteridol ( Figure S1 , Supporting Information). No consistent significant downregulation in cell viability was measured for the cells incubated with UPy-Gd compared to the cells treated with Gadoteridol, indicating that Gd(III) remains stably chelated after DOTA has been conjugated to the UPy moiety.
Relaxivity Measurements
Water proton longitudinal and transverse relaxivities r 1 and r 2 reflect to what extent a contrast agent shortens the longitudinal and transverse relaxation times T1 and T2 of surrounding water molecules. First, it was tested whether the covalent coupling of a UPy group to the Gd(III)-DOTA complex influences its ability for water relaxation. UPy-Gd was dissolved in phosphate buffered saline (PBS) pH 7.4 and its effect on relaxation was measured at 1.4 T (60 MHz) with nuclear magnetic resonance (NMR) spectroscopy. A linear relation was found; both T1 and T2 were shortened with increasing UPy-Gd concentration resulting in r 1 ≈ 7.40 mm −1 s −1 and r 2 ≈ 9.02 mm −1 s −1 ( Figure 3A) . Changes in pH did not have much impact, as R values measured at 1 × 10 −3 m were almost identical under basic or acidic conditions ( Figure 3A ). UPy-Gd was then mixed with the UPy-PEG hydrogelator to analyze the effect of incorporation in a supramolecular polymer network. When measured in combination with 2 wt% UPy-PEG hydrogelator, no significant changes in relaxivity were observed. This applied to both r 1 and r 2 while in solution (sol) at pH 9.0 or in hydrogel form (gel) at pH 7.4 ( Figure 3B ). Furthermore, no notable changes in relaxivities were observed when varying the concentration of hydrogelator between 0 and 8 wt% ( Figure 3C ). Finally, UPy-Gd and its non-UPy-functionalized counterpart Gadoteridol were separately incorporated in a 10 wt% hydrogel and measured in a 1.5 T (64 MHz) clinical MRI scanner. Relaxivities were found to be in a similar range as observed with NMR, with r 1 ≈ 4.97 mm −1 s −1 for UPy-Gd ( Figure 3D ). Furthermore, the measured r 1 ≈ 4.48 mm
for Gadoteridol is well in line with values reported in the literature. [36, 37] In view of the aggregation behavior of this supramolecular system it is surprising that neither pH changes nor incorporation in a high concentration hydrogel matrix influences the relaxivity of the UPy-Gd. Following classic SolomonBloembergen-Morgan theory, grafting or immobilization of the paramagnetic UPy-Gd would enhance relaxivity as a result of a decrease in molecular tumbling. [38] One explanation for the absence of significant relaxivity changes could be the high exchange rates that monovalent UPy guests experience in the UPy-PEG network, as was recently disclosed with fluorescent UPy guests. [34] In addition, the OEG linker may be long and flexible enough to give the Gd(III)-DOTA moiety freedom to move and tumble, despite the supramolecular anchoring interactions with the UPy-PEG hydrogelator. Another possibility is that water accessibility is reduced due to, e.g., backfolding into www.advancedsciencenews.com www.advhealthmat.de the polymer stack, counteracting the effect of a decreased tumbling rate.
Retention of Contrast Agents in Hydrogel
A retention experiment was performed to verify the supramolecular incorporation of UPy-Gd into the UPy-PEG hydrogel. After a two-week period, both the releasates and the hydrogels taken at several time points were analyzed in a 1.5 T clinical MRI scanner to quantify the amount of contrast agent. Gadoteridol was found in both the hydrogels and release samples from the first 24 h, and correctly adds up to ≈ 100% at each time point ( Figure 4A ). Release of Gadoteridol within a day occurred via an expected typical diffusion profile. In contrast, release samples from hydrogels with UPy-Gd contained almost no contrast agent, while the hydrogels themselves exhibited strongly enhanced signals for the whole duration of the experiment ( Figure 4B ). The amount of UPy-Gd released from the hydrogels equates to 23% after two weeks. This value is well in line with the previously reported rate of erosion of the hydrogel itself, which is not significantly influenced upon addition of guest molecules at this concentration. [10] While dynamics at the molecular level are likely high, these retention results imply that at a macroscopic level the UPy-Gd cannot diffuse and escape from the UPy-PEG hydrogel. In fact, as a result of the supramolecular interactions, UPy-Gd is kept in place with the transient polymer network, and is only liberated by erosion of the hydrogel. Therefore, we can propose that the signal arising from the UPy-Gd MRI label serves as an accurate marker for the actual location of the UPy-PEG hydrogel carrier.
Ex Vivo Injections in Pig Heart and MRI
UPy-PEG hydrogel is under extensive investigation for delivery of therapeutics in the heart post myocardial infarction. An explanted pig heart was therefore chosen to investigate whether the supramolecular labeling technique enhances the contrast and accuracy of localization in tissue. Four injections of 10 wt% UPy-PEG hydrogels pH 9.0 functionalized with UPy-Gd and four injections of 10 wt% UPy-PEG hydrogels pH 9.0 physically mixed with Gadoteridol were performed, at 1 × 10 −3 m and 2.5 × 10 −3 m [Gd(III)]. Two 10 wt% UPy-PEG hydrogels without contrast agent were injected as control. The heart was embedded in agar 1 h after injections and stored at 4 °C. The following day T 1 -weighted images were made in a 1.5 T MRI scanner. The resulting images show an enormous difference between integrated UPy-Gd and Gadoteridol with regard to intensity and location ( Figure 5A,B) . UPy-PEG hydrogels with integrated UPy-Gd (1-4) appear as hyperintense concentrated spots with easy to identify sharp borders between hydrogel and adjacent tissue. A 3D rendered image of the complete heart illustrates this effectively ( Figure 5C ). Due to the local high content of contrast agent the T1 is shortened to such an extent that no difference in intensity between the two concentrations UPy-Gd can be seen visually detected. On the contrary, injection sites of UPy-PEG hydrogel mixed with Gadoteridol (i-iv) are more difficult to locate. They appeared as broadened spots over an area much larger than the injected hydrogel volume. The 3D image displays all four of the Gadoteridol injections and accentuates the large, vague locations with diffuse borders ( Figure 5D ). For these formulations the higher concentration of 2.5 × 10 −3 m Gadoteridol improved the overall visibility as compared to that for 1 × 10 −3 m concentration formulations. The control injections without contrast agent were not visible.
A volume assessment on the visualized spots was performed to identify whether they match the injected volume, and to what degree the material distributes throughout the tissue ( Figure  S2 , Supporting Information). The outcome of this analysis is determined by the (arbitrary) intensity threshold that is set to distinguish between tissue with contrast agent and normal tissue. By using a variable threshold, the volumes with signal At the edges, voxels are partially filled with UPy-Gd, causing the average signal increase to be lower when compared to the signal increase of voxels entirely filled with UPy-Gd. As these voxels are at the edge of the volume, their relative contribution is substantial. These partial volume effects are proposed to be amplified even more by the distribution in the cardiac tissue. It may be expected that injected UPy-PEG hydrogel will be distributed heterogeneously in the muscle tissue, caused by the fibrous structure. Due to this phenomenon some areas and voxels are only partially filled with hydrogel and UPy-Gd. While no difference was noticeable upon visual inspection of the different concentrations, the observation described above could justify utilizing the higher concentration of UPy-Gd for optimal volume analysis. In the injections with Gadoteridol (i-iv) much lower concentrations of contrast agent are present as can be concluded from the much lower maximum signal increase ( Figure S2 , Supporting Information). Interestingly, when reducing the threshold the volumes of the Gadoteridol injections increase much faster, which is proposed to be due to the fact that the unconjugated contrast agent was not confined to the location of the injection. Instead it diffused to a larger circumferential region, causing a very low concentration gradient, when compared to the steep concentration gradient in the UPy-Gd injections. Therefore, no reliable hydrogel volumes could be obtained from these data.
Analysis of the MRI scans supports the results from the retention experiment and demonstrates the value of supramolecular integration of the contrast agent with the hydrogel network. While the Gadoteridol injections were mostly still visible, they do not provide representative or detailed information about the location and shape of the hydrogel. Quick diffusion of Gadoteridol from the hydrogel into the surrounding tissue occurred. In vivo at 37 °C the diffusion rate would be even faster, and likely accelerated as a result of the high blood perfusion in the cardiac tissue and increased pressure caused by cardiac contractions. [39] Also, imaging difficulty is amplified due to higher background signal, motion artifacts, and limitations in scanning time. These factors even further reduce the feasibility and relevance of Gadoteridol for use in the imaging of hydrogels, especially when viewing the far better images obtained with the UPy-Gd contrast agent.
In Vivo MRI of Intramyocardial Catheter Injected Hydrogel
Finally, an in vivo feasibility study was performed by intramyocardial injection of 2.5 × 10 −3 m UPy-Gd in a 10 wt% UPy-PEG hydrogel formulation (this equates to a mass percentage of 4% or a molar percentage of 28% UPy-Gd relative to the used UPy-PEG) via the percutaneous approach. The injection was performed via a minimally invasive procedure through the groin using a catheter designed for injection of the viscous UPy-PEG hydrogel precursor. [25] Postinjection, the hydrogel was visualized with phase sensitive inversion recovery reconstruction sequences ( Figure 5E ). At the intended injection site the hydrogel could be located, verifying that also in vivo at 37 °C the hydrogel maintained form at the injection site without immediate dispersion throughout the tissue. Furthermore, it means that contrast enhancement with the employed UPy-Gd concentration is sufficient for clear and fast in vivo imaging.
Adv. Healthcare Mater. 2018, 7, 1701139 Figure 5 . Selected slices of MRI scans of a pig heart ex vivo injected with 10 wt% UPy-PEG hydrogel in combination with UPy-Gd or Gadoteridol, and 3D rendered images of the whole heart. Injection spots 1 and 2 are 1 × 10 −3 m UPy-Gd and spots 3 and 4 are 2.5 × 10 −3 m UPy-Gd. Injection spots i and ii are 1 × 10 −3 m Gadoteridol and spots iii and iv are 2.5 × 10 −3 m Gadoteridol. A) Two clear injection sites with UPy-Gd and one with Gadoteridol. B) One injection site with Gadoteridol and one with UPy-Gd. C) 3D rendered image of the left side of the pig heart with four injection sites with UPy-Gd. D) 3D rendered image of the right side of the pig heart with four injection sites with Gadoteridol. E) Postinjection image of an in vivo intramyocardial injection in a pig heart with 10 wt% UPy-PEG hydrogel containing 2.5 × 10 −3 m UPy-Gd, applied via a catheter inside the MRI system. www.advancedsciencenews.com www.advhealthmat.de
Conclusion
The contrast agent UPy-Gd is designed as an MRI label for supramolecular incorporation into the UPy-PEG hydrogel. At a macroscopic level the UPy-Gd retains within the hydrogel network, and provides high contrast and precise information on the 3D shape, location, and volume of the hydrogel. In contrast, physically mixed Gadoteridol does not accurately reflect the morphology or shape of injected UPy-PEG hydrogel due to rapid leakage by diffusion. We demonstrated that the UPy-Gdlabeled hydrogel is perfectly visible in vivo after minimally invasive catheter injection in a beating heart. We foresee that this labeling and visualization method for supramolecular hydrogels can be used for sequential measurements of the same specimen to determine 3D structure, location, and degradation or erosion rate of hydrogels. This crucial information is proposed to aide in the continuing development, fine-tuning, and modulation of hydrogel properties for in vivo applications. Yet, in case alternative imaging modalities are preferred, the DOTAGd label is envisioned to be substitutable for other desired reporters. Finally, catheter-guided injections of viscous materials in the beating myocardium inside the MRI scanner are desired for accurate targeting of specific locations, but are not the clinical standard yet. We think that the approach presented, allowing for an immediate postinjection feedback by MRI for confirmation of correct injection, will be particularly valuable for the future development of guided injectable therapies.
Experimental Section
Materials: All reagents and chemicals were obtained from commercial sources at the highest purity available and used without further purification unless stated otherwise. Water was purified on an EMD Millipore Milli-Q Integral Water Purification System. PBS tablets were purchased from Sigma-Aldrich. Gadoteridol was purchased from Sigma-Aldrich (1287631 USP). Millicell hanging cell culture inserts (PIEP12R48/MCEP24H48) were purchased from EMD Millipore. A fresh explanted pig heart was obtained from LifeTec Group. Data processing and analysis was performed in Excel 2010 and Origin 2015. MRI scans were processed with RadiAnt DOCIM viewer. 3D rendered images of MRI scans were made with Avizo 9.2.0.
Instrumentation: 1 H NMR and 13 C NMR spectra were recorded on a 400 MHz NMR (Varian Mercury Vx or Varian 400MR) operating at 400 MHz for 1 H NMR and 100 MHz for 13 C NMR. Proton chemical shifts were reported in ppm downfield from tetramethylsilane (TMS) and carbon chemical shifts in ppm downfield from TMS using the resonance of the deuterated solvent as internal standard. Abbreviations used are s: singlet; d: doublet; t: triplet; q: quartet; m: multiplet. Mass spectrometry (LC-ESI-MS) was performed using a Shimadzu LC-10 AD VP series HPLC coupled to a diode array detector (Finnigan Surveyor PDA Plus detector, Thermo Electron Corporation) and an Ion-Trap (LCQ Fleet, Thermo Scientific) where ions were created via electrospray ionization (ESI). LC-analyses on precursor molecules were performed using an Alltech Alltima HP C 18 3 µm column using an injection volume of 1-4 µL, a flow rate of 0.2 mL min −1 , and typically a gradient (5-100% in 10 min, held at 100% for a further 3 min) of CH 3 CN/H 2 O (both containing 0.1% formic acid) at 298 K. Reversed phase column chromatography was performed on a Biotage Isolera Spektra One Flash Chromatography system using Biotage KP-C18 HS SNAP cartridge.
Synthesis of UPy-Gd: The precursors UPy-C 6 -U-C 12 -C-OEG 12 -NH 2 and N-hydroxysuccinimide activated DOTA (DOTA-NHS-xTFA) were synthesized as described elsewhere. [40] [41] [42] (i) UPy-C 6 -U-C 12 -C-OEG 12 -NH 2 (280 mg, 0.26 mmol) was dissolved in dimethylformamide (DMF) (5 mL) and DOTA-NHS-xTFA (383 mg, 0.53 mmol) and DiPEA (0.62 mL, 3.57 mmol) were added. The reaction mixture was stirred overnight and subsequently the solvent was removed under vacuum and twice co-evaporated with toluene. Eluting over reversed phase C18 column with a gradient ACN/water of 5/95 to 80/20 afforded the intermediate UPy-DOTA (360 mg, 94%) as a white powder after freeze-drying. 1 (ii) Intermediate UPy-DOTA (360 mg, 0.25 mmol) was dissolved in H 2 O (10 mL) and the pH was adjusted to 7.1 using 1 m NaOH. Gd(OAc) 3 • 4.47H 2 O (123 mg, 0.30 mmol) in H 2 O (4 mL, dissolved by shortly heating) was added, and the pH was again adjusted to 7.0 using 1 m NaOH. The solution was stirred at room temperature (RT) overnight. The solvent was removed under vacuum. Eluting over reversed phase C18 column with a gradient ACN/water of 5/95 to 80/20 first eluted free Gd and thereafter eluted the desired product. Pooling of the product fractions afforded the final product UPy-Gd (250 mg, 63%) as a white powder after freeze-drying. The absence of free gadolinium in the product was confirmed with the xylenol orange test. 
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Preparation of Hydrogels and Liquid Precursors with Contrast Agents:
UPy-PEG hydrogel precursor solutions were prepared by dissolving the UPy-PEG hydrogelator powder in PBS at elevated pH (e.g., 10 mg in 90 µL PBS pH 11.7 for a 10 wt% hydrogel solution) and stirring at 70 °C for 1 h. Afterward the viscous solution was cooled to RT with a resulting pH of ≈ 9.0. To obtain UPy-PEG hydrogels with the desired concentration of contrast agent, the hydrogel precursor solutions were prepared at twice the intended wt%. UPy-Gd or Gadoteridol was also dissolved in PBS pH 7.4 at twice the desired concentrations. Contrast agent and hydrogel solutions were then combined in a 1 to 1 (v/v) ratio and stirred at 50 °C for 10 min to get completely dissolved homogeneous solutions with the desired wt% hydrogel and concentration of either UPy-Gd or Gadoteridol. For gelation for in vitro measurements the solutions were brought back to neutral pH by addition of 1.4 µL of 1 m HCl per 100 µL hydrogel solution. Retention and Leakage of Contrast Agents from Hydrogel: Hydrogel precursor solutions with 1 × 10 −3 m UPy-Gd or 1 × 10 −3 m Gadoteridol were prepared as described above. From each solution ten hydrogels were made in Millicell inserts by transferring 100 µL into the insert and subsequently adding 1.4 µL of 1 m HCl on top. The inserts were then left for incubation for 1 1. The inserts with hydrogels were placed in a 24-well plate with 500 µL PBS per well as release medium and put in a 37 °C incubator with 95% humidity. At set time points (1, 5, 24, 48, 96, 168, 240 , and 336 h) one of the hydrogels was removed from the setup and stored under humid conditions in the fridge to prevent drying out of the hydrogel. For all the other hydrogels the PBS was removed, stored, and replaced with fresh PBS. At the end of the experiment a minimum of three release samples and one hydrogel is obtained for each time point. After two weeks the hydrogels (still in the inserts) and release samples collected in Eppendorf tubes were put in a green styrofoam block and scanned in a Philips Ingenia MR 1.5 Tesla system. Longitudinal relaxivity measurements were performed using the same imaging parameters and data processing as just described for UPy-Gd and Gadoteridol. Furthermore, tubes with 500 µL PBS and known concentrations of Gadoteridol (0.01, 0.025, 0.05, 0.1, and 0.25 × 10 −3 m) or UPy-Gd (0.01, 0.025, 0.05, and 0.1 × 10 −3 m) were scanned in parallel to determine a standard curve between [Gd(III)] and T1 for the release samples. Also hydrogels in inserts with known concentrations of UPy-Gd (0.25, 0.5, and 1 × 10 −3 m) were scanned in parallel to determine standard curves between [Gd(III)] and T1 for the hydrogels in inserts. For Gadoteridol relaxation data obtained in the previous MRI experiment were used to calculate the concentrations. Data are represented as percentage contrast agent released and percentage remaining in hydrogel. All release values are reported as mean ± SD, n = 3. All values of percentage remaining in hydrogel are from single hydrogels, except the last data point at 336 h that is mean ± SD, n = 2.
Ex Vivo Injections Pig Heart and MRI: UPy-PEG hydrogel precursor solutions of pH 9.0 with UPy-Gd or Gadoteridol were prepared as described above, at 1.0 and 2.5 × 10 −3 m [Gd(III)]. The next morning a frozen pig heart was thawed until at room temperature. For each condition two injections of 200 µL were performed with a 1 mL syringe and a 23G needle. The injection depth was ≈4-5 mm. Injections with UPy-Gd were performed in the anterior and lateral wall of the left ventricle and the Gadoteridol injections in the infero-posterior wall and the right ventricle. As control two injections of hydrogel solution without contrast agent were injected. The heart was embedded in a 4 wt% agarose solution at 55 °C in a plastic container. This setup was cooled to 4 °C overnight for complete gelation of the agarose. The following day scans were made in a Philips Ingenia MR 1.5 Tesla system. Scans were T 1 -weighted 3D Turbo Field with echo times (1.93, 3.54, 5.14, 6.74, and 8.34 ms) and a repetition time of 10.21 ms. The field of view was 192 × 144 × 960 mm, reconstructed to 1.25 × 1.25 × 5 mm. Two slices of the scans are presented in Figure 4 (slices 127 and 146). Furthermore a 3D image was rendered to visualize all injections. As quantification of Gd-based contrast agents is not trivial, volumes were determined of regions expressing increased signal intensities, related to injection of Gd(III) in the heart. By defining a threshold, regions with high signal were selected that contain Gd(III). Total hydrogel volumes were determined by multiplying the number of voxels by the volume per voxel. By varying the threshold, the size of the volume per injection site changes, providing information about the distribution.
In Vivo Intramyocardial Injection in a Pig and MRI: All in vivo experiments were conducted in accordance with the national guidelines and with prior approval by the Animal Experimentation Committee of the Utrecht University, the Netherlands. A six-month old female Dalland landrace pig (70 kg) was sedated with an intramuscular injection of midazolam (0.4 mg kg −1 ), ketamine (10 mg kg −1 ), and atropine (0.5 mg kg −1 ). General anesthesia was induced with intravenous infusion of sodium thiopental (5 mg kg −1 ) and maintained with continuous intravenous infusion of midazolam (0.5 mg kg −1 h −1 ), sufentanil (2.5 µg kg −1 h −1 ), and pancuronium bromide (0.1 mg kg −1 h −1 ). Hereafter, the pig was placed in the Philips Ingenia MR 1.5 Tesla system. UPy-PEG liquid hydrogel precursor pH 9.2 with 2.5 × 10 −3 m UPy-Gd was prepared as just described and 200 µL of this solution was percutaneously injected in the myocardium through the groin using a catheter designed for injection of the viscous UPy-PEG hydrogel precursor. [25] Statistical Analysis: In Figure 4B the "released" samples are displayed as a simple mean ± SD from three samples. The "remaining in gel" samples are single samples, except for the last data point that is the mean ± SD from two samples. For the MTT assay in Figure S1 (Supporting Information) each condition was measured in fourfold. The mean and SD of all conditions were normalized to the mean of untreated cells (n = 4). An unpaired two-tailed t-test was performed with GraphPad Quickcalcs to identify statistically significant differences in metabolic activity of cells treated with UPy-Gd versus Gadoteridol. P values below 0.05 are indicated with a single *, P values below 0.01 with double *, and P values below 0.001 with triple *. P values for concentrations that were identified as statistically different are noted in the legend.
Supporting Information
Supporting Information is available from the Wiley Online Library or from the author.
